Skip to main content

Spark Therapeutics doses first Pompe disease patient in study of experimental gene therapy

The company wants to enroll up to 20 patients with the rare, inherited disease for the study.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.